Target: ₹2,821CMP: ₹2,531.50After years of growth led by distribution reach and prescription volume, Mankind Pharma is re-orienting towards research-led, niche and specialty therapies where competition is thinner. A calculated move into low-competition specialty niches is a more achievable route to above-market growth if execution follows. .Chronic segment’s outperformance has narrowed to 1.1x the IPM rate in FY26 from 1.2-1.3x historically. . The ₹13,770-crore acquisition of Bharat Serums and Vaccines (BSV) is the clearest expression of the pivot, making Mankind Pharma the domestic gynaecology leader (10.4 per cent share) and adding high-barrier biologics.Mankind Pharma’s large medical representative force is the engine that commercialises acquired and in-licenced products, deepening their reach faster than the original owners could, and giving it a low-cost lever to scale future launches. But cross-selling, fertility clinic reach and export registrations have been built over several years, and thus BSV is a long-term contributor that strengthens the franchise instead of adding near-term growth.We value Mankind Pharma at 44x FY28F EPS of ₹64.1 for a target price of ₹2,821. At about 51x trailing earnings, the stock currently trades at a premium to domestic formulation-led peers, a premium we feel its chronic and-specialty quality justifies but which leaves limited room for slippage on the acute segment’s volume recovery or the BSV ramp-up from new launches.Published on July 7, 2026